Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. (Q37071199)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

main subject

gram-positive bacteria

0 references

author

Helen Giamarellou

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Garyphallia Poulakou

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

225-243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Investigational new drugs for the treatment of resistant pneumococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Device-associated nosocomial infections in 55 intensive care units of 8 developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Staphylococcus aureus: superbug, super genome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

High-level vancomycin-resistant enterococci causing hospital infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Approaches to vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Staphylococcus aureus with reduced susceptibility to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Oritavancin--an investigational glycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Clinical experience with recently approved antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Thrombocytopenia associated with linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Hematologic effects of linezolid: summary of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Serotonin toxicity associated with the use of linezolid: a review of postmarketing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Investigational treatments for postoperative surgical site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Severe myopathy and possible hepatotoxicity related to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Effect of dalbavancin on the normal intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Bactericidal activity and resistance development profiling of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Dalbavancin: a novel lipoglycopeptide antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Telavancin: in vitro activity against staphylococci in a biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Mechanism of action of oritavancin and related glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Glycopeptide antibiotics: from conventional molecules to new derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Antimicrobial resistance: the example of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Vancomycin tolerance in enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

De-escalation therapy in ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.225

10.1517/13543784.17.2.225

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18230056%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference